Evidence map›Paper›PMID 31988467›Full record

ArticleMucosal immunology2020

Protein kinase 2 (CK2) controls CD4

Wei Yang, Sara A Gibson, Zhaoqi Yan, Hairong Wei, Jiahui Tao, Bingdong Sha, Hongwei Qin, Etty N Benveniste

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Biometabolites ofNutrients · 2023
    Article
  7. Frontiers in immunology · 2023
    Article
  8. Protein Kinase CK2 Controls CD8Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  9. Review
  10. Review
  11. Protein Kinase CK2 Regulates B Cell Development and Differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wei YangDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Sara A GibsonLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Zhaoqi YanDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Hairong WeiDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jiahui TaoDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bingdong ShaDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Hongwei QinDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. hqin@uab.edu.
Etty N BenvenisteDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. tika@uab.edu.
University of Alabama at Birmingham · USUniversity of North Carolina at Chapel Hill · US

Funding

IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
Therapeutic Intervention of the JAK/STAT Pathway for NeuroinflammationR01NS057563 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BENVENISTE, ETTY N · 2008 to 2017
$2.7M
The Role of CK2 in Glioblastoma DevelopmentR01CA194414 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BENVENISTE, ETTY N · 2016 to 2020
$1.7M
PERK inhibition as a therapeutic approach for Alzheimer's diseaseR21AG058839 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SHA, BINGDONG · 2018 to 2019
$408k
NCI NIH HHS R01 CA194414NIAID NIH HHS T32 AI007051NIAMS NIH HHS P30 AR048311NIA NIH HHS R21 AG058839NINDS NIH HHS R01 NS057563
6 · The paper itself

Abstract

Crohn's disease (CD), one of the major forms of inflammatory bowel disease (IBD), is characterized by chronic inflammation of the gastrointestinal tract and associated with aberrant CD4

Indexed as

Disease SusceptibilityAnimalsBiomarkersCD4-Positive T-LymphocytesCell DifferentiationCell SurvivalColitisDisease Models, AnimalGene ExpressionImmunophenotypingIntestinal MucosaLymphocyte ActivationMiceProtein Serine-Threonine KinasesBiomarkersProtein Serine-Threonine Kinases

Identifiers

PMID31988467
PMCPMC7382987
OpenAlexW3000871980

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.